2月龄和6周岁儿童DTaP与IPV或MPV-AC同时接种7天内不良事件主动监测
结果显示联合接种未增加不良事件风险或严重程度,6周岁儿童不良事件发生率高于2月龄,主要为局部不良事件增加。
要点
- DTaP1联合IPV1与单独DTaP1相比,总体、局部和全身不良事件发生率差异均无统计学意义。
- DTaP5联合MPV-AC2与单独DTaP5相比,总体、局部和全身不良事件发生率差异均无统计学意义。
- 6周岁儿童不良事件发生率18.78%高于2月龄儿童的7.35%,主要表现为局部不良事件增加。
核心结论
- DTaP与IPV、MPV-AC同时接种均具有良好安全性,未增加不良事件风险和严重程度。
- 6周岁儿童不良事件发生率高于2月龄儿童,主要体现为局部不良事件增加。
研究设计与样本
- 2月龄儿童接种DTaP1单独或联合IPV1,6周岁儿童接种DTaP5单独或联合MPV-AC2。
- 观察接种后7天内不良事件发生情况,比较发生率、分级、症状和间隔,组间比较采用χ²检验或Fisher确切概率法。
主要发现
- 2月龄组不良事件发生率为7.35%,显著低于6周岁组的18.78%(χ²=106.675,P<0.001)。
- DTaP1组与DTaP1+IPV1组总体(6.85%比7.53%,χ²=0.231,P=0.631)、局部(1.07%比0.49%,P=0.189)和全身(6.21%比7.04%,χ²=0.370,P=0.543)不良事件发生率差异均无统计学意义。
- DTaP5组与DTaP5+MPV-AC2组总体(20.14%比17.74%,χ²=2.182,P=0.140)、局部(18.38%比16.08%,χ²=2.160,P=0.142)和全身(3.91%比3.40%,χ²=0.437,P=0.509)不良事件发生率差异均无统计学意义。
- DTaP1组与DTaP1+IPV1组全身不良事件均以1级为主,仅发热发生率差异有统计学意义(1.07%比2.78%,χ²=4.397,P=0.036)。
- DTaP5组与DTaP5+MPV-AC2组局部不良事件均以2级为主,各临床症状发生率差异均无统计学意义;红肿、硬结分级均主要为2级(≥5 cm);4组不良事件均主要集中在≤1天。
临床怎么用
- DTaP可与IPV或MPV-AC同时接种,不增加不良事件风险和严重程度。
- 6周岁儿童接种DTaP5后局部不良事件发生率较高,应加强接种后局部反应监测和告知。
- 接种后不良事件多发生在≤1天,应重点关注接种后早期观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the safety of simultaneous administration of the diphtheria, tetanus, and acellular pertussis vaccine (DTaP), inactivated poliovirus vaccine (IPV), and group A and group C meningococcal polysaccharide vaccine (MPV-AC) in children aged 2-month and 6-year-old. Methods: From June to July 2025, children at vaccination clinics in Wuxi City were enrolled, including 2-month-old children (receiving DTaP1 alone or combined with IPV1) and 6-year-old children (receiving DTaP5 alone or combined with MPV-AC2). The occurrence of adverse event (AE) within 7 days post-vaccination was observed, and the incidence, severity grading, symptoms, and intervals were compared. The comparison of the incidence of AE between groups was performed using the Chi-square test or Fisher's exact test. Results: The incidence of AE in the 2-month-old group (1 688) was 7.35%, significantly lower than that in the 6-year-old group (2 348; 18.78%; χ²=106.675, P<0.001). Comparison of DTaP1 versus DTaP1+IPV1 showed no significant differences in the overall (6.85% vs. 7.53%, χ²=0.231, P=0.631), local (1.07% vs. 0.49%, P=0.189), or systemic (6.21% vs. 7.04%, χ²=0.370, P=0.543) AE rates. Similarly, no significant differences were observed in the overall (20.14% vs. 17.74%, χ²=2.182, P=0.140), local (18.38% vs. 16.08%, χ²=2.160, P=0.142), or systemic (3.91% vs. 3.40%, χ²=0.437, P=0.509) AE rates between the DTaP5 and DTaP5+MPV-AC2 groups. In the DTaP1 and DTaP1+IPV1 groups, systemic AE were predominantly grade 1, manifesting primarily as fever (1.07% vs. 2.78%, χ²=4.397, P=0.036), crying (1.71% vs. 1.97%, χ²=0.116, P=0.734), and decreased appetite/anorexia (1.07% vs. 1.15%, χ²=0.018, P=0.895). Notably, a statistically significant difference was observed only for fever. In the DTaP5 and DTaP5+MPV-AC2 groups, local AE were primarily grade 2, with the most common symptoms being redness and swelling (15.54% vs. 13.58%, χ²=1.791, P=0.181), pruritus (7.33% vs. 7.47%, χ²=0.017, P=0.898), pain (4.89% vs. 3.77%, χ²=1.757, P=0.185), and induration (4.20% vs. 3.47%, χ²=0.847, P=0.357). No significant differences were found in the incidence rates of any symptoms between the DTaP5 and DTaP5+MPV-AC2 groups. Redness and swelling, and induration predominantly presented as grade 2 reactions (≥5 cm in diameter). The majority of post-vaccination AE in all four groups occurred within ≤1 day after immunization. Conclusion: Simultaneous administration of DTaP with IPV and MPV-AC shows a favorable safety profile, without an increase in the risk or severity of AE. Notably, 6-year-old children have a higher incidence of AE compared with 2-month-old children, primarily manifesting as increased local AE. 目的: 分析2月龄和6周岁儿童同时接种无细胞百白破联合疫苗(DTaP)与脊髓灰质炎灭活疫苗(IPV)、A群C群脑膜炎球菌多糖疫苗(MPV-AC)的安全性。 方法: 2025年6至7月,在无锡市接种门诊纳入2月龄(DTaP1单独或联合IPV1)、6周岁(DTaP5单独或联合MPV-AC2)儿童,观察接种后7 d内不良事件(AE)发生情况,比较发生率、分级、症状和间隔。组间比较采用χ²检验或Fisher确切概率法。 结果: 2月龄组儿童(1 688名)的AE发生率为7.35%,显著低于6周岁组儿童(2 348名)的18.78%(χ²=106.675,P<0.001)。DTaP1组、DTaP1+IPV1组的总体(6.85% 比 7.53%,χ²=0.231,P=0.631)、局部(1.07% 比 0.49%,P=0.189)和全身(6.21% 比 7.04%,χ²=0.370,P=0.543)AE发生率差异均无统计学意义;DTaP5组、DTaP5+MPV-AC2组的总体(20.14% 比 17.74%,χ²=2.182,P=0.140)、局部(18.38% 比 16.08%,χ²=2.160,P=0.142)和全身(3.91% 比 3.40%,χ²=0.437,P=0.509)AE发生率差异均无统计学意义。DTaP1组、DTaP1+IPV1组全身AE均以1级为主,主要症状为发热(1.07% 比 2.78%,χ²=4.397,P=0.036)、哭闹(1.71% 比 1.97%,χ²=0.116,P=0.734)和食欲不振/厌食(1.07% 比 1.15%,χ²=0.018,P=0.895),2组仅发热发生率差异有统计学意义。DTaP5组、DTaP5+MPV-AC2组局部AE均以2级为主,主要症状为红肿(15.54% 比13.58%,χ²=1.791,P=0.181)、瘙痒(7.33% 比 7.47%,χ²=0.017,P=0.898)、疼痛(4.89% 比 3.77%,χ²=1.757,P=0.185)和硬结(4.20% 比 3.47%,χ²=0.847,P=0.357),2组各临床症状发生率差异均无统计学意义。其中,红肿、硬结分级均主要为2级(≥5 cm)。4组接种后AE均主要集中在≤1 d。 结论: DTaP与IPV、MPV-AC同时接种均具有良好安全性,未增加AE风险和严重程度,6周岁儿童AE发生率高于2月龄,主要体现为局部AE增加。.
引用
- Yang X, Xiu SX, Wang LL, et al. [Active surveillance of adverse event within 7 days of single versus simultaneous administration of diphtheria, tetanus, and acellular pertussis combined vaccine in children aged 2-month and 6-year-old]. Zhonghua Yu Fang Yi Xue Za Zhi. 2026. PMID: 42331533. doi:10.3760/cma.j.cn112150-20250811-00779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。